This is despite several setbacks for drug IP owners at the Unified Patent Court Register for limited access Register to receive our newsletter and gain limited access to subscriber content. Register now Subscribe to unlock unlimited access Get news, unique …

… Real Estate Strategy director at Genentech, said the updates it is … future. “It allows both Genentech and the city to move … As part of the purchase, Genentech would take ownership of parts … Cabot Road, currently within the Genentech campus. In addition to the …

… shaping the industry include: Roche (Genentech), Bristol Myers Squibb, Merck …

… Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend …

… Repare Therapeutics, RIN Institute, Roche-Genentech, Sanofi, Seagen, Servier, and Takeda … Repare Therapeutics, RIN Institute, Roche-Genentech, Sanofi, Seagen, Servier, and … Repare Therapeutics, RIN Institute, Roche-Genentech, Sanofi, Servier, Seagen, and …

… , Agios, ASLAN Pharmaceuticals, Bayer, Roche, Genentech, AstraZeneca, Immunomedics, Lilly, Merrimack, Millennium …

… Novartis, Pfizer, Roche/Genentech, Seagen, and UCB; receiving … Pfizer, and Roche/Genentech; receiving travel expenses from … Novartis, Pfizer, Roche/Genentech, and Seagen; and being … Novartis, Pfizer, Roche/Genentech, Seagen, and UCB. Pfeiler …

… controlled studies involving omalizumab (Xolair; Genentech, Novartis) and mepolizumab (Nucala; GSK …

… slow disease progression. For instance, Genentech Inc., a US-based biotechnology …

… ., Regeneron Pharmaceuticals Inc., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Santen …